A Phase I trial of preoperative eniluracil plus 5-fluorouracil and radiation for locally advanced or unresectable adenocarcinoma of the rectum and colon

International Journal of Radiation Oncology Biology Physics

Volumn 58, Issue 3, 2004, Pages 779-785

  Czito, Brian G ^a   Hong, Timothy J ^a   Cohen, Darrel P ^a   Tyler, Douglas S ^a   Lee, Catherine G ^a   Anscher, Mitchell S ^a   Ludwig, Kirk A ^a   Seigler, Hilliard F ^a   Mantyh, Christopher ^a   Morse, Michael A ^a   Lockhart, Albert C ^b   Petros, William P ^c   Honeycutt, Wanda ^a   Spector, Neil L ^d   Ertel, Phillip J ^d   Mangum, Steve G ^d   Hurwitz, Herbert I ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

^c WEST VIRGINIA UNIVERSITY   (United States)

^d GLAXOSMITHKLINE   (United States)

Author keywords

5 Fluorouracil; Colorectal cancer; Eniluracil; Phase I; Radiotherapy

Indexed keywords

CHEMOTHERAPY; DISEASES; PATIENT TREATMENT; RADIOTHERAPY; SURGERY; TOXICITY; TUMORS;

CHEMORADIOTHERAPY; DOSE-LIMITING TOXICITY;

ONCOLOGY;

5 ETHYNYLURACIL; FLUOROURACIL;

ADENOCARCINOMA; ADULT; AGED; ANOREXIA; ANUS SPHINCTER; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; COLON ADENOCARCINOMA; COLORECTAL CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTITIS; DIARRHEA; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERBILIRUBINEMIA; HYPOKALEMIA; MALE; MULTIMODALITY CANCER THERAPY; NAUSEA; NEUTROPENIA; PATIENT ATTITUDE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PREOPERATIVE CARE; PRIORITY JOURNAL; RADIATION DOSE; RASH; RECTUM CARCINOMA; RECTUM DISEASE; SEPSIS; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 10744222901     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(03)01567-0     Document Type: Article

References (36)

1. Jemal A., Thomas A., Murray T., et al. Cancer statistics, 2002. CA Cancer J Clin. 52:2002;23-47.
2. Douglass H. Jr, Moertel C., Mayer R., et al. Survival after postoperative combination treatment of rectal cancer. N Engl J Med. 315:1986;1294-1295.
3. Krook J., Moertel C., Gunderson L., et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med. 324:1991;709-715.
4. O'Connell M., Martenson J., Wieand H., et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med. 331:1994;502-507.
5. Minsky B., Kemeny N., Cohen A., et al. Preoperative high-dose leucovorin/5-fluorouracil and radiation therapy for unresectable rectal cancer. Cancer. 67:1991;2859-2866.
6. Minsky B. Role of adjuvant therapy in adenocarcinoma of the rectum. Semin Surg Oncol. 17:1999;189-198.
7. Porter D., Chesnut W., Merrill B., et al. Mechanism-based inactivation of dihydropyrimidine dehydrogenase by 5-ethynyluracil. J Biol Chem. 267:1992;5236-5242.
8. Spector T., Harrington J., Porter D. 5-Ethynyluracil (776C85) Inactivation of dihydropyrimidine dehydrogenase in vivo . Biochem Pharmacol. 46:1993;2243-2248.
9. Ahmed F., Johnston S., Cassidy J., et al. Eniluracil treatment completely inactivates dihydropyrimidine dehydrogenase in colorectal tumors. J Clin Oncol. 17:1999;2439-2445.
10. Diasio R. Clinical implications of dihydropyrimidine dehydrogenase inhibition. Oncology (Huntingt) 1999;13(7 Suppl. 3):17-21.
11. Baccanari D., Davis S., Knick V., et al. 5-Ethynyluracil (776C85) A potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil . Proc Natl Acad Sci USA. 90:1993;11064-11068.
12. Naguib F., el Kouni M., Cha S. Enzymes of uracil catabolism in normal and neoplastic tissues. Cancer Res. 45:1985;5405-5412.
13. Diasio R., Harris B. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet. 16:1989;215-237.
14. Diasio R. Improving fluorouracil chemotherapy with novel orally administered fluoropyrimidines. Drugs. 58:(Suppl. 3):1999;119-126.
15. Schilsky R., Hohneker J., Ratain M., et al. Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer. J Clin Oncol. 16:1998;1450-1457.
16. Baker S., Khor S., Adjei A., et al. Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase. J Clin Oncol. 14:1996;3085-3096.
17. Baker S., Diasio R., O'Reilly S., et al. Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil. J Clin Oncol. 18:2000;915-926.
18. Fleming R., Milano G., Gaspard M., et al. Dihydropyrimidine dehydrogenase activity in cancer patients. Eur J Cancer. 29A:1993;740-744.
19. Etienne M., Lagrange J., Dassonville O., et al. Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol. 12:1994;2248-2253.
20. Lu Z., Zhang R., Diasio R. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver Population characteristics, newly identified deficient patients, and clinical implications in 5-fluorouracil chemotherapy . Cancer Res. 53:1993;5433-5438.
21. Mani S., Hochster H., Beck T., et al. Multicenter phase II study to evaluate a 28-day regimen of oral fluorouracil plus eniluracil in the treatment of patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 18:2000;2894-2901.
22. Fischel J., Etienne M., Spector T., et al. Dihydropyrimidine dehydrogenase A tumoral target for fluorouracil modulation . Clin Cancer Res. 1:1995;991-996.
23. Cao S., Rustum Y., Spector T. 5-Ethynyluracil (776C85) Modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma . Cancer Res. 54:1994;1507-1510.
24. Spector T., Cao S., Rustum Y., et al. Attenuation of the antitumor activity of 5-fluorouracil by (R)-5-fluoro-5,6-dihydrouracil. Cancer Res. 55:1995;1239-1241.
25. Pazdur R., Douillard J., Skillings J., et al. Multicenter phase III study of 5-fluorouracil or UFT in combination with leucovorin (LV) in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol. 18:1999;263a.
26. Meropol N., Rustum Y., Petrelli N., et al. A phase I and pharmacokinetic study of oral uracil, ftorafur, and leucovorin in patients with advanced cancer. Cancer Chemother Pharmacol. 37:1996;581-586.
27. Hoff P., Wenske C., Medgyesy D., et al. Phase I and pharmacokinetic (PK) study of the novel oral fluoropyrimidine, S-1. Proc Am Soc Clin Oncol. 18:1999;173a.
28. Hoff P., Janjan N., Saad E., et al. Phase I study of preoperative oral uracil and tegafur plus leucovorin and radiation therapy in rectal cancer. J Clin Oncol. 18:2000;3529-3534.
29. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med. 336:1997;980-987.
30. Kapiteijn E., Marjnen C., Nagtegaal I., et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 345:2001;638-646.
31. Janjan N., Khoo V., Abbruzzese J., et al. Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer The M. D. Anderson Cancer Center experience . Int J Radiat Oncol Biol Phys. 44:1999;1027-1038.
32. Grann A., Feng C., Wong D., et al. Preoperative combined modality therapy for clinically resectable uT3 rectal adenocarcinoma. Int J Radiat Oncol Biol Phys. 49:2001;987-995.
33. Onaitis M., Noone R., Hartwig M., et al. Neoadjuvant chemoradiation for rectal cancer Analysis of clinical outcomes from a 13-year institutional experience . Ann Surg. 233:2001;778-785.
34. Petrelli N., Wieand S., Colangelo L., et al. Phase III randomized trial of preoperative versus postoperative multimodality therapy in patients with carcinoma of the rectum (NSABP R-03). Proc Am Soc Clin Oncol. 20:2001;490.
35. Dunst J., Reese T., Sutter T., et al. Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer. J Clin Oncol. 20:2002;3983-3991.
36. Twelves C., Boyer M., Findlay M., et al. Capecitabine (Xeloda) improves resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma. Eur J Cancer. 37:2001;597-604.